Article

Alcon repurchases one million shares

Alcon repurchases one million shares

Hünenberg, Switzerland-Alcon Inc. said it intends to purchase up to one million common shares by Dec. 31 from the public to cover employee equity compensation plans. Nestlé SA and Novartis AG said they will not participate in the program.

Alcon has approximately 70 million shares that are publicly traded out of total outstanding shares of approximately 300 million, the company said in a prepared statement. Alcon has been engaged in share repurchases to cover employee equity compensation grants since going public in 2002.

Earlier this year, the board suspended share repurchases under all of its prior plans due to the anticipated share purchase and sale between Nestlé and Novartis.

Nestlé currently owns 52% of outstanding common shares and Novartis currently owns just under 25% as a result of that transaction, however, these ownership interest percentages are not expected to change as a result of the this share repurchase plan.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.